Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
INZY
INZY | US
5.28
USD-0.26
-4.69%
INZY | US
About INZY
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
5.28
Open
5.48
High
5.59
Low
5.28
Inozyme Pharma Inc. a clinical-stage biopharmaceutical company focuses on developing novel therapeutics for the treatment of vasculature soft tissue and skeleton diseases in the United States. The company's lead product candidate is INZ-701 a soluble recombinant genetically engineered and fusion protein which is in Phase 1/2 clinical trials for the treatment of ENPP1 and ABCC6 deficiency as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston Massachusetts.
View LessINZY | US
Risk
56.3
Sharpe
0.82
Luna's Score
46/100
Recommendation
Hold
Luna says (INZY | US)
What's Working
What's not Working
High Short-term Volatility
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
59.9%1 month
56.3%3 months
57.3%6 months
51.9%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
3.66
Debt to equity
0.49
Debt to assets
0.30
Ent. to EBITDA
-4.25
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-92.10M
MarketCap
354.28M
MarketCap(USD)
354.28M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-88.56
Short ratio
17.95
Short perc.
5.88
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.69
Range1M
0.83
Range3M
2.03
Volumes: Market Activity
Rel. volume
0.92
Price X volume
909.48K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -4.25 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.66 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 57.31 | - | Lower Risk |
| Debt to Equity | 0.49 | -1.23 | Expensive |
| Debt to Assets | 0.30 | 0.25 | Expensive |
| Market Cap | 354.28M | - | Emerging |
